The economics of active surveillance for prostate cancer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To review the economics of managing low-risk prostate cancer with active surveillance compared with other standard therapies. RECENT FINDINGS: The expenses of caring for men with prostate cancer vary depending on treatment modality chosen and appear to be escalating. Costs are generally lowest with traditional watchful waiting and highest with radiation therapy. Compared with immediate treatment, active surveillance can result in a net per-patient savings of $12 194 at 5 years and $4329 at 10 years. Active surveillance demonstrates lower 5-year costs over other initial treatments as long as fewer than 70% exit active surveillance in any given year and at least 12% of men remain on active surveillance at year 5. Yearly surveillance biopsy reduces the average simulated cost savings at 10 years by $4951 per patient. SUMMARY: Active surveillance represents a cost-effective strategy for managing low-risk prostate cancer, as the majority of men remain without additional treatment over time. Prostate biopsy is the highest expenditure associated with active surveillance, and increasing the frequency of prostate biopsy will reduce the cost-effectiveness of this approach.

Original languageEnglish (US)
Pages (from-to)278-282
Number of pages5
JournalCurrent Opinion in Urology
Volume23
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Prostatic Neoplasms
Economics
Biopsy
Costs and Cost Analysis
Prostate
Watchful Waiting
Therapeutics
Cost Savings
Health Expenditures
Cost-Benefit Analysis
Radiotherapy

Keywords

  • active surveillance
  • costs
  • economics
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

The economics of active surveillance for prostate cancer. / Dall'Era, Marc.

In: Current Opinion in Urology, Vol. 23, No. 3, 05.2013, p. 278-282.

Research output: Contribution to journalArticle

@article{8b3e999476fd43b8bd3981f777640910,
title = "The economics of active surveillance for prostate cancer",
abstract = "PURPOSE OF REVIEW: To review the economics of managing low-risk prostate cancer with active surveillance compared with other standard therapies. RECENT FINDINGS: The expenses of caring for men with prostate cancer vary depending on treatment modality chosen and appear to be escalating. Costs are generally lowest with traditional watchful waiting and highest with radiation therapy. Compared with immediate treatment, active surveillance can result in a net per-patient savings of $12{\^a}€Š194 at 5 years and $4329 at 10 years. Active surveillance demonstrates lower 5-year costs over other initial treatments as long as fewer than 70{\%} exit active surveillance in any given year and at least 12{\%} of men remain on active surveillance at year 5. Yearly surveillance biopsy reduces the average simulated cost savings at 10 years by $4951 per patient. SUMMARY: Active surveillance represents a cost-effective strategy for managing low-risk prostate cancer, as the majority of men remain without additional treatment over time. Prostate biopsy is the highest expenditure associated with active surveillance, and increasing the frequency of prostate biopsy will reduce the cost-effectiveness of this approach.",
keywords = "active surveillance, costs, economics, prostate cancer",
author = "Marc Dall'Era",
year = "2013",
month = "5",
doi = "10.1097/MOU.0b013e32835f4b6b",
language = "English (US)",
volume = "23",
pages = "278--282",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The economics of active surveillance for prostate cancer

AU - Dall'Era, Marc

PY - 2013/5

Y1 - 2013/5

N2 - PURPOSE OF REVIEW: To review the economics of managing low-risk prostate cancer with active surveillance compared with other standard therapies. RECENT FINDINGS: The expenses of caring for men with prostate cancer vary depending on treatment modality chosen and appear to be escalating. Costs are generally lowest with traditional watchful waiting and highest with radiation therapy. Compared with immediate treatment, active surveillance can result in a net per-patient savings of $12 194 at 5 years and $4329 at 10 years. Active surveillance demonstrates lower 5-year costs over other initial treatments as long as fewer than 70% exit active surveillance in any given year and at least 12% of men remain on active surveillance at year 5. Yearly surveillance biopsy reduces the average simulated cost savings at 10 years by $4951 per patient. SUMMARY: Active surveillance represents a cost-effective strategy for managing low-risk prostate cancer, as the majority of men remain without additional treatment over time. Prostate biopsy is the highest expenditure associated with active surveillance, and increasing the frequency of prostate biopsy will reduce the cost-effectiveness of this approach.

AB - PURPOSE OF REVIEW: To review the economics of managing low-risk prostate cancer with active surveillance compared with other standard therapies. RECENT FINDINGS: The expenses of caring for men with prostate cancer vary depending on treatment modality chosen and appear to be escalating. Costs are generally lowest with traditional watchful waiting and highest with radiation therapy. Compared with immediate treatment, active surveillance can result in a net per-patient savings of $12 194 at 5 years and $4329 at 10 years. Active surveillance demonstrates lower 5-year costs over other initial treatments as long as fewer than 70% exit active surveillance in any given year and at least 12% of men remain on active surveillance at year 5. Yearly surveillance biopsy reduces the average simulated cost savings at 10 years by $4951 per patient. SUMMARY: Active surveillance represents a cost-effective strategy for managing low-risk prostate cancer, as the majority of men remain without additional treatment over time. Prostate biopsy is the highest expenditure associated with active surveillance, and increasing the frequency of prostate biopsy will reduce the cost-effectiveness of this approach.

KW - active surveillance

KW - costs

KW - economics

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84876417895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876417895&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e32835f4b6b

DO - 10.1097/MOU.0b013e32835f4b6b

M3 - Article

C2 - 23449496

AN - SCOPUS:84876417895

VL - 23

SP - 278

EP - 282

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -